Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network.
Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network.
复制标题
DOI：
10.1097/icu.0000000000000262
复制
发表时间：
2016-05
影响因子：
3.7
通讯作者：
Stone T
中科院分区：
文献类型：
--
作者：
Baker CW;Jiang Y;Stone T
糖尿病视网膜病变（DR）和糖尿病黄斑水肿（DME）是导致视力丧失的常见眼部疾病。糖尿病视网膜病变临床研究网络 (DRCRnet) 是由国家眼科研究所和国家糖尿病、消化和肾脏疾病研究所支持的私人和学术机构合作组织，对糖尿病眼病进行了 13 年的研究。这篇评论将讨论该网络去年的发现，当时报告了他们的一些最重要的贡献。 DRCRnet 报道玻璃体内注射贝伐珠单抗、雷珠单抗和阿柏西普均可改善 DME 患者的视力。基线视力为 20/30 至 20/40 时，所有药物均具有相似的功效。当基线视力为 20/50 或更差时，阿柏西普带来了卓越的视力改善。方案 S 将全视网膜光凝术与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变 (PDR) 进行比较，发现注射组的视力结果和手术率并不逊色。次要结果表明，雷珠单抗支持注射作为 PDR 的可能替代治疗方法改善了功能结果。 DRCRnet 帮助阐明了 DME 和 PDR 的各种治疗方法的作用，并将继续评估这些危及视力的疾病的治疗方法。
Diabetic retinopathy (DR) and diabetic macular edema (DME) are common eye diseases leading to vision loss. The Diabetic Retinopathy Clinical Research Network (DRCRnet), a collaboration of private and academic practices supported by the National Eye Institute and the National Institute of Diabetes, Digestive and Kidney Diseases have studied diabetic eye disease for 13 years. This review will discuss the network’s findings over the last year, when some of their most important contributions were reported. The DRCRnet reported intravitreal bevacizumab, ranibizumab and aflibercept all improve visual acuity in DME. With baseline vision of 20/30 to 20/40, all agents had similar efficacy. With baseline vision of 20/50 or worse, aflibercept resulted in superior visual improvement. Protocol S, which compared panretinal photocoagulation to intravitreal injections of ranibizumab for proliferative diabetic retinopathy (PDR), found vision outcomes and surgery rates were not inferior in the injection group. Secondary outcomes indicate improved functional results with ranibizumab supporting injections as a possible alternative treatment for PDR. The DRCRnet has helped clarify the role of various treatments for both DME and PDR, and will continue to evaluate treatments for these vision-threatening conditions.